HighGravityDataBioMarin Pharmaceutical — Aug 6, 2026 release
Fiscal 2026 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-26-000015
Showing in the filing
Interest expense related to Amicus financing (annualized)
“approximately $200 million”
Period
No period stated
Measure
GAAP-tied
Source
Prose
All guidance in this release · 22
VOXZOGO full-year 2026 revenue (CEO quote) for FY2026
“at least $1 billion”
Peak revenue for GALAFOLD for FY2030
“approximately $1.4 billion”
Peak revenue for POMBILITI + OPFOLDA for FY2030
“approximately $1.2 billion”
Cost reductions from Amicus acquisition (GAA… for FY2028
“approximately $280 million”
Cost reductions on a GAAP basis for FY2028
“approximately $280 million”
Cost reductions from Amicus acquisition (Non… for FY2028
“approximately $220 million”
GALAFOLD and POMBILITI + OPFOLDA, combined, … for FY2030
“over 60%”
Gross leverage target for FY2027
“below 2.5 times”
Interest expense associated with the financing
“approximately $200 million on an annualized basis”
Interest expense related to Amicus financing…
“approximately $200 million”
Total Revenues for FY2026
“$3,875 to $3,925”
Total Revenues Midpoint Growth (Y/Y) for FY2026
“21%”
Metabolic Conditions for FY2026
“$2,725 to $2,775”
Metabolic Conditions Midpoint Growth (Y/Y) for FY2026
“31%”
VOXZOGO Revenue for FY2026
“$1,000 to $1,050”
VOXZOGO Midpoint Growth (Y/Y) for FY2026
“11%”
Other Revenues for FY2026
“$100 to $125”
Metabolic Conditions Revenue for FY2026
“Unchanged”
Non-GAAP Diluted EPS for FY2026
“$4.90 to $5.10”
Non-GAAP Diluted EPS Midpoint Growth (Y/Y) for FY2026
“59%”
Weighted-Average Diluted Shares Outstanding … for FY2026
“approximately 200 million”
Combined company tax rate assumption for Non… for FY2026
“22%”
Exhibit 99.1 · the passage around this item
… earlier in the release
• Guidance reflects post-close contributions from Amicus beginning April 27, 2026. • BioMarin will continue to include interest expense related to the Amicus financing in both GAAP and Non‑GAAP financial results. Based on current rates, interest expense associated with the financing is estimated at approximately $200 million on an annualized basis, with Term Loans and Senior Notes scheduled to mature after 2030. Item Provided on May 4, 2026 Updated August 6, 2026 Midpoint Growth (Y/Y) Total Revenues $3,825 to $3,925 $3,875 to $3,925 21% Metabolic Conditions $2,725 to $2,775 Unchanged 31% VOXZOGO $975 to $1,025 $1,000 to $1,050 11% Other Revenues (1) $100 to $125 Unchanged Non-GAAP Diluted EPS (2)(3)(4) $4.85 to $5.05 $4.90 to $5.10 59% (1) Other Revenues includes KUVAN, ROCTAVIAN, and royalties. (2) Refer to Non-GAAP Information beginning on page 10 of this press release for definition of Non-GAAP Diluted EPS. (3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding. (4) Non-GAAP Diluted EPS guidance assumes a combined company tax rate of 22%. BioMarin will host a conference call and webcast to discuss second quarter 2026 financial results today, Thursday, August 6, 2026, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com. U.S./Canada Dial-in Number: 800-715-9871 Replay Dial-in Number: 800-770-2030 International Dial-in Number: 646-307-1963 Replay International
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.